A practical guide to the management of hypertension in renal transplant recipients

Drugs

Volumn 58, Issue 6, 1999, Pages 1011-1027

  Olyaei, Ali J ^a   DeMattos, Angelo M ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG CONTRAINDICATION; EDEMA; EXTRACELLULAR SPACE; FATIGUE; FLUSHING; GRAFT REJECTION; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; IMPOTENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; KIDNEY TRANSPLANTATION; MUSCLE WEAKNESS; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THYROTOXICOSIS; VERTIGO;

EID: 0033393848     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958060-00005     Document Type: Review

References (118)

1. 1. US Renal Data System: USRDS 1997 Annual Report. The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease. Bethesda (MD), 1997
2. 2. Raine AE. Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol Dial Transplant 1995; 10 Suppl. 1: 95-100
3. 3. Braun WE, Marwick TH. Coronary artery disease in renal transplant recipients. Cleve Clin J Med 1994; 61: 370-85
4. 4. Kokado Y, Takahara S, Kameoka H, et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. Transplant Proc 1996; 28: 1600-2
5. 5. Cosio FG, Falkenhain ME, Pesavento TE, et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997; 29: 419-27
6. 6. Collins R, Peto R, Godwin J, et al. Blood pressure and coronary heart disease. Lancet 1990; 336: 370-1
7. 7. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Pt 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
8. 8. Mammen NI, Chacko N, Ganesh G, et al. Aspects of hypertension in renal allograft recipients: a study of 1000 live renal transplants. Br J Urol 1993; 71: 256-8
9. 9. Tripathi K, Prakash J. Refractory hypertension in transplant recipients. Transplant Proc 1992; 24: 1790-0
10. 10. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471-5
11. 11. Curtis JJ. Management of hypertension after transplantation. Kidney Int 1993; 43 Suppl.: S45-9
12. 12. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182-93
13. 13. Kaye D, Thompson J, Jennings G, et al. Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993; 88: 1101-9
14. 14. Textor SC. De novo hypertension after liver transplantation. Hypertension 1993; 22: 257-67
15. 15. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Pt 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
16. 16. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217-22
17. 17. Bennett, WM, Porter GA. Cyclosporine-associated hypertension [editorial]. Am J Med 1988; 85: 131-3
18. 18. Charnick SB, Nedelman JR, Chang CT, et al. Description of blood pressure changes in patients beginning cyclosporin A therapy. Ther Drug Monit 1997; 19: 17-24
19. 19. Kutkuhn B, Hollenbeck M, Westhoff A, et al. Renin secretion and captopril stimulation in hypertensive renal transplant recipients. Urol Int 1994; 52: 82-6
20. 20. Bennett WM, Porter GA. Cyclosporine-associated hypertension [editorial]. Am J Med 1988; 85: 131-3
21. 21. van den Dorpel MA, van den Meiracker AH, Lameris TW, et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28: 304-7
22. 22. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-65
23. 23. Kasiske BL. Risk factors for cardiovascular disease after renal transplantation. Miner Electrolyte Metab 1993; 19: 186-95
24. 24. Fervenza FC, Lafayette RA, Alfrey EJ, et al. Renal artery stenosis in kidney transplants. Am J Kidney Dis 1998; 31: 142-8
25. 25. Curtis JJ, Luke RG, Whelchel JD, et al. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med 1983; 308: 377-81
26. 26. Kuo PC, Petersen J, Semba C, et al. CO2 angiography: a technique for vascular imaging in renal allograft dysfunction. Transplantation 1996; 61: 652-4
27. 27. Crook ED. The role of hypertension, obesity, and diabetes in causing renal vascular disease. Am J Med Sci 1999; 317: 183-8
28. 28. Mathur VS, Kerlan RK, Melzer J, et al. Acute renal allograft dysfunction secondary to suprarenal arterial stenosis: a case series and review of the literature. Clin Transplant 1998; 12: 333-42
29. 29. Wong W, Fynn SP, Higgins RM, et al. Transplant renal artery stenosis in 77 patients: does it have an immunological cause? Transplantation 1996; 61: 215-9
30. 30. Curlis JJ, Luke RG, Diethelm AG, et al. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985; 2: 739-42
31. 31. Thompson JF, Fletcher EW, Wood RF, et al. Control of hypertension after renal transplantation by embolisation of host kidneys. Lancet 1984; 2: 424-7
32. 32. Fricke L, Doehn C, Steinhoff J, et al. Treatment of post-transplant hypertension by laparoscopic bilateral nephrectomy? Transplantation 1998; 65: 1182-7
33. 33. Teixeira MC, Mazucchi F., Nahas WC, et al. Peripheral renin activity predicts blood pressure control after bilateral nephrectomy in renal transplant patients. Transplant Proc 1997; 29: 220-1
34. 34. Szabo A, Patschan O, Kuttler B, et al. Hypertension accelerates the pace of chronic graft dysfunction in the rat. Transplant Int 1998; 11 Suppl. 1: S10-4
35. 35. Kirkman RL, Strom TB, Weir MR, et al. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982; 34: 347-51
36. 36. Benediktsson H, Chea R, Davidoff A, et al. Antihypertensive drug treatment in chronic renal allografl rejection in the rat: effect on structure and function. Transplantation 1996; 62: 1634-42
37. 37. First MR, Neylan JF, Rocher LL, et al. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4: Suppl.: S30-6
38. 38. Schachter M. Cyclosporine A and hypertension. J Hypertens 1988; 6: 511-6
39. 39. Roullet JB, Xue H, Burdman EA, et al. Cardiovascular consequences of immunosuppressive drug treatment: a comparative study of cyclosporine A and cyclosporine G. Transplant Proc 1995; 27: 346-7
40. 40. Sudhir K, MacGregor JS, DeMarco T, et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994; 90: 3018-23
41. 41 Lee DB. Cyclosporine and the renin-angiotensin axis. Kidney Int 1997; 52: 248-60
42. 42. Elzinga LW, Rosen S, Bennel WM. Dissociation of glomcrular filtration rale from the tubulointerstitial fibrosis in experimental chronic cyclosporine neprhopathy: role of sodium intake. J Am Soc Nephrol 1993; 4: 214-21
43. 43. Sander M, Lyson T, Thomas GD, et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 1996; 9: 121-38S
44. 44. Carvalho MJ, van den Meiracker AH, Boomsa F, et al. Role of sympathetic nervous system in cyclosporine-induced rise in blood pressure. Hypertension 1999; 34: 102-6
45. 45. de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28: 631-67
46. 46. Macleod AM, Thomson AW. FK 506: an immunosuppressant for the 1990s? Lancet 1991; 337: 25-7
47. 47. Whitworth JA. Studies on the mechanisms of glucocorticoid hypertension in humans. Blood Press 1994; 3: 24-32
48. 48. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213-24
49. 49. Schalekamp MA, Wenting GJ, Man in't Veld AJ. Pathogcnesis of mineralocorticoid hypertension. Clin Endocrinol Metab 1981; 10:397-418
50. 50. Kuhlmann D, Ragan C, Ferrebee JW, et al. Toxic effects of desoxycorticosterone esters in dogs. Science 1939; 90: 496-7
51. 51. Mantero F, Armanini D, Boscaro M, et al. Steroids and hypertension. J Steroid Biochem Mol Biol 1991; 40: 35-44
52. 52. Grunfeld JP. Glucocorticoids in blood pressure regulation. Horm Res 1990; 34: 111-3
53. 53. Abdelhamid S, Muller-Lobeck H, Pahl S, et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Int Med 1996; 156: 1190-5
54. 54. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996; 19: 1-8
55. 55. Whitworth JA, Butkus A, Coghlan JP, et al. 9-alpha-Fluoro-cortisol-induced hypertension: a review. J Hypertens 1986; 4: 133-9
56. 56. Schulak JA, Hricik DE. Steroid withdrawal after renal transplantation. Clin Transplant 1994; 8 (Pt 2): 211-6
57. 57. Hricik DE, Lautman J, Bartucci MR, et al. Variable effects of steroid withdrawal on hlood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232-5
58. 58. Pirsch JD, Armbrust MJ, Knechtle SJ, et al. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc 1991; 23 (Pt 2): 1363-4
59. 59. Hricik DE, Kupin WL, First MR. Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 1994; 4: Suppl.: S10-6
60. 60. Lipkin GW, Tucker B, Giles M, et al. Ambulatory hlood pressure and left ventricular mass in cyclosporin-and non-cyclosporin-treated renal transplant recipients. J Hypertens 1993; 11: 439-42
61. 61. Meyer MM. Post-transplant hypertension. In: Bennett WM, McCarron DA, editors. Pharmacology and management of hypertension. New York: Churchill Livingstone, 1994: 181-215
62. 62. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-92
63. 63. Moser M. Hypertension can be treated effectively without increasing the cost of care. J Hum Hypertens 1996; 10: Suppl. 2: 533-8
64. 64. Reams GP. Renal effects of antihypertensive drugs In: Bennett WM, McCarron DA, editors. Pharmacology, pharmacology and management of hypertension. New York: Churchill Livingstone, 1994: 29-54
65. 65. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure: dosing guidelines for adults. American College of Physicians. 4th ed. Philadelphia (PA): American College of Physicians, 1999
66. 66. Bia MJ, Tyler K. Evidence that calcium channel blockade prevents cyclosporine-induced exacerbation of renal ischemic injury. Transplantation 1991; 51: 293-5
67. 67. Dawidson I, Rooth P, Fisher D, et al. Verapamil ameliorates acute cyclosporine A (CsA) nephrotoxicity and improves immunosuppression after cadaver renal transplantation. Transplant Proc 1989; 21 (Pt 2): 1511-3
68. 68. Dawidson I, Rooth P, Fry WR, et al. Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 1989; 48: 575-80
69. 69. Dawidson I, Rooth P, Alway C, et al. Verapamil prevents post-transplant delayed function and cyclosporine A nephrotoxicity. Transplant Proc 1990; 22: 1379-80
70. 70. Dawidson I, Rooth P, Lu C, et al. Verapamil improves the outcome after cadaver renal transplantation. J Am Soc Nephrol 1991; 2: 983-90
71. 71. Martinez-Castelao A, Hueso M, Sanz. V, et al. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int 1998; 68 Suppl.: S130-S134
72. 72. Schrier RW, Arnold PE, Van Putten VJ, et al. Cellular calcium in ischemic acute renal failure: role of calcium entry blockers. Kidney Int 1987; 32: 313-21
73. 73. Bia MJ, Tyler KA. Effect of cyclosporine on renal ischemic injury. Transplantation 1987; 43: 800-4
74. 74. Wagner K, Albrecht S, Neumayer HH. Prevention of post-transplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol 1987; 7: 287-91
75. 75. Neumayer HH, Lopping A, Velten M, et al. Effect of cyclosporine A on post-ischemic acute renal failure in conscious dogs: role of vasoactive renal hormones. Transplant Proc 1987; 19: 4035-40
76. 76. Lee DB. Cyclosporine and the renin-angiotensin axis. Kidney Int 1997; 52: 248-60
77. 77. Ruggenenti P, Perico N. Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-11
78. 78. Sorensen SS, Skovbon H, Eiskjaer H, et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol Dial Transplant 1992; 7: 69-78
79. 79. Duggan KA, Macdonald GJ, Charlesworth JA, et al. Verapamil prevents post-transplant oliguric renal failure. Clin Nephrol 1985; 24: 289-91
80. 80. Morales JM, Rodriguez-Paternina E, Araque A, et al. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporinc therapy: a 5-year prospective randomized study. Transplant Proc 1994; 26: 2598-9
81. 81 Palmer HP, Dawidson I, Sagalowsky A, et al. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52: 640-5
82. 82. McMillen MA, Lewis T, Jaffe BM, et al. Verapamil inhibition of lymphocyte proliferation and function in vitro. J Surg Res 1985; 39: 76-80
83. 83. Birx DL., Berger M, Fleisher TA. The interference of T cell activation by calcium channel blocking agents. J Immunol 1984; 133: 2904-9
84. 84. Schlueter WA, Batlle DC. Renal effects of antihypertensive drugs. Drugs 1989; 37: 900-25
85. 85. Iabichella ML, Dell'Omo G, Melillo E, et al. Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients. Hypertension 1997; 29: 751-6
86. 86. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31
87. 87. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5
88. 88. Pesavento TE, Jones PA, Julian BA, et al. Amlodipine increases cyclosporinc levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol 1996; 7: 831-5
89. 89. Guan D, Wang R, Lu J, et al. Effects of nicardipine on blood cyclosporinc levels in renal transplant patients. Transplant Proc 1996; 28: 1311-2
90. 90. Nadelmann J, Frishman WH. Clinical use of beta-adrenoceptor blockade in systemic hypertension. Drugs 1990; 39: 862-76
91. 91. Huysmans FT, van Heusden FH, Wetzels JF, et al. Antihyperlensive effect of beta blockade in renal transplant recipients with or without host kidneys. Transplantation 1988; 46: 234-7
92. 92. Hausberg M, Burenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862-8
93. 93. Wikstrand J. Primary prevention in patients with hypertension: comments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study. Am Heart J 1988; 116 (Pt 2): 338-47
94. 94. Kaplan NM. Critical comments on recent literature. SCRAAPHY about MAPHY from HAPPHY Am J Hypertens 1988; 1 (Pt 1): 428-30
95. 95. Ritz E, Orth SR, Strzelczyk P. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens 1997; 15 Suppl.: S21-6
96. 96. Moser M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. J Am Coll Cardiol 1997; 29: 1414-21
97. 97. Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Am Heart J 1999; 138: 238-45
98. 98. Traindl O, Falger S, Reading S, et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55: 1309-13
99. 99. Bergman SM, Curtis JJ. Possible mediators in hypertension: renal factors. Semin Nephrol 1996; 16: 134-9
100. 100. Bochicchio T, Sandoval G, Ron O, et al. Fosinopril prevents hyperfiltralion and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990; 38: 873-9
101. 101. del Castillo D, Campistol JM, Guirado L, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998; 68 Suppl: SI35-SI39
102. 102. Sennesael J, Lamote J, Violet I, et al. Comparison of pcrindopril and amlodipine in cyclosporine-trealed renal allograft recipients. Hypertension 1995; 26: 436-44
103. 103. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43: 419-25
104. 104. van der Schaaf MR, Hene RJ, Floor M, et al. Hypertension after renal transplantation: calcium channel or converting enzyme blockade? Hypertension 1995; 25: 77-81
105. 105. Sennesael JJ, Lamote JG, Violet I, et al. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis 1996; 27: 701-8
106. 106. Grekas D, Dioudis C, Kalevrosoglou I, et al. Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors. Kidney Int 1996; 55 Suppl.: S97-100
107. 107. Grekas D, Dioudis C, Kalevrosoglou I, et al. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation. Clin Nephrol 1995; 44: 299-302
108. 108. Shihab FS, Bennett WM, Tanner AM, et al. Angiotensin II blockade decreases TGF-betal and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660-73
109. 109. De'Oliveira JM, Price DA, Fisher ND, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997; 52: 771-7
110. 110. Gaston RS, Julian BA, Curtis JJ. Post-transplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24: 1-11
111. 111. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101: 71S-82S
112. 112. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300
113. 113. Swan SK. Diuretic strategies in patients with renal failure. Drugs 1994; 48: 380-5
114. 114. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886-94
115. 115. Bittar AE, Ratcliffe PJ, Richardson AJ, et al. Hyperparathyroidism, hypertension and loop diuretic medication in renal transplant recipients. Nephrol Dial Transplant 1989; 4: 740-4
116. 116. Parfill AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3-9
117. 117. West C, Carpenter BJ, Hakala TR. The incidence of gout in renal transplant recipients. Am J Kidney Dis 1987; 10: 369-72
118. 118. Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients Ann Intern Med 1995; 123: 481-7